证券日报网讯8月12日晚间，浙江医药（600216）发布公告称，2025年8月11日，公司完成回购，通过上 海证券交易所系统以集中竞价方式累计回购公司股份13，723，200股，占公司目前总股本的1.43%。 ...

Group 1 - The company Zhejiang Medicine announced the completion of a share buyback on August 11, 2025, through the Shanghai Stock Exchange [1] - A total of 13.72 million shares were repurchased, accounting for 1.43% of the company's total share capital [1] - The highest buyback price was 16.09 CNY per share, the lowest was 13.31 CNY per share, and the average buyback price was 14.57 CNY per share, with a total expenditure of approximately 200 million CNY (excluding transaction fees) [1] Group 2 - The repurchased shares will be used for future employee stock ownership plans or equity incentives [1]

Core Viewpoint - Zhejiang Medicine announced the completion of a share buyback, acquiring approximately 13.72 million shares, which represents 1.43% of the company's total equity, at an average price of 14.57 CNY per share, totaling around 200 million CNY in funds used [1] Group 1: Share Buyback Details - The company completed the buyback on August 11, 2025, through a centralized bidding method on the Shanghai Stock Exchange [1] - The highest buyback price was 16.09 CNY per share, while the lowest was 13.31 CNY per share [1] - The total number of shares repurchased was approximately 13.72 million [1] Group 2: Revenue Composition - For the year 2024, the revenue composition of Zhejiang Medicine is as follows: human nutritional products accounted for 50.1%, pharmaceuticals for 48.85%, and other businesses for 1.05% [1] - The contribution from other businesses includes 0.64% from other categories and 0.41% from additional services [1] Group 3: Market Capitalization - As of the report, Zhejiang Medicine's market capitalization stands at 15 billion CNY [1]

证券代码：600216 证券简称：浙江医药 公告编号：2025-033 浙江医药股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购方案首次披露日 2025/4/15，由公司董事长李男行先生提议 回购方案实施期限 2025 年 4 月 15 日~2026 年 4 月 14 日 预计回购金额 1亿元~2亿元 回购价格上限 20.46元/股 □减少注册资本 √用于员工持股计划或股权激励 回购用途 □用于转换公司可转债 □为维护公司价值及股东权益 实际回购股数 13,723,200股 实际回购股数占总股本比例 1.43% 实际回购金额 199,982,725元 实际回购价格区间 13.31元/股~16.09元/股 一、 回购审批情况和回购方案内容 公司本次回购股份符合相关法律法规的规定及公司回购股份方案的要求。本 次回购方案实际执行情况与已披露的回购方案不存在差异，公司已按披露的方案 完成回购。 本次股份回购不会对公司正常经营活动、财务状况及未来发展等产生重大影 响 ...

证券代码：600216 证券简称：浙江医药 公告编号：2025-033 浙江医药股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/15，由公司董事长李男行先生提议 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 日~2026 月 14 日 | 4 | 月 | 15 | 年 | 4 | | 预计回购金额 | 1亿元~2亿元 | | | | | | | 回购价格上限 | 20.46元/股 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 实际回购股数 | 13,723,200股 | | | | | | | 实际回购股数占总股本比例 | 1.43% ...

格隆汇8月12日丨浙江医药(600216.SH)公布，2025年8月11日，公司完成回购，通过上海证券交易所系 统以集中竞价方式累计回购公司股份1372.32万股，占公司目前总股本的1.43%，回购最高价格为16.09 元/股，最低价格为13.31元/股，回购均价为14.57元/股，使用资金总额为人民币2亿元(不含交易费用)。 ...

浙江医药公告，2025年8月11日，公司完成回购，通过上海证券交易所系统以集中竞价方式累计回购公 司股份1372.32万股，占公司目前总股本的1.43%，回购最高价格为16.09元/股，最低价格为13.31元/股， 回购均价为14.57元/股，使用资金总额为人民币2亿元(不含交易费用)。此次回购股份用于后续实施员工 持股计划或股权激励。 ...

Core Insights - The report highlights the importance of CFOs in listed companies, with the total salary scale for CFOs in A-share companies reaching 4.27 billion yuan in 2024 [1] - The average annual salary for CFOs in the raw material pharmaceutical sector is 661,200 yuan [1] Salary Distribution - The top three highest-paid CFOs are Gong Yuda from Guobang Pharmaceutical with 1.93 million yuan, Li Qirong from Zhejiang Pharmaceutical with 1.84 million yuan, and Hou Ning from Xinhua Pharmaceutical with 1.57 million yuan [1] - The salary distribution shows that 44% of CFOs earn below 500,000 yuan, 44% earn between 500,000 and 1 million yuan, and 12% earn above 1 million yuan [1] Age and Education Distribution - CFOs aged 40-50 constitute the majority at 36%, while those aged 60 and above account for 5% [1] - The educational background of CFOs shows that 65% hold a bachelor's degree, 21% have a master's degree, and only 2% have a high school diploma [1] Salary Changes - Liu Qingke from Huangshan Capsule experienced the largest salary decrease at 19.04%, while Qian Dan from Nengte Technology saw the highest salary increase at 100.58% [1]

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] - Among the CFOs, those aged 40-50 represent the majority at 36%, while those aged 60 and above account for 5% [1] - The youngest CFO currently in office is 33 years old, from XinNuoWei, named Dai Long [1] Group 2 - The average annual salary of CFOs in the A-share raw material pharmaceutical companies is 661,200 yuan [2] - The salary distribution shows that 44% of CFOs earn below 500,000 yuan, while another 44% earn between 500,000 and 1 million yuan, and 12% earn above 1 million yuan [2] - The top three highest-paid CFOs are Gong Yuda from Guobang Pharmaceutical at 1.93 million yuan, Li Qirong from Zhejiang Pharmaceutical at 1.84 million yuan, and Hou Ning from Xinhua Pharmaceutical at 1.57 million yuan [2]

Core Insights - The report highlights the significant role of CFOs in listed companies, with the total salary scale for A-share CFOs reaching 4.27 billion yuan in 2024, averaging 814,800 yuan per year [1][2] Salary Distribution - The average salary for CFOs in the A-share raw material pharmaceutical companies is 661,200 yuan, with 44% earning below 500,000 yuan, 44% between 500,000 and 1 million yuan, and 12% above 1 million yuan [2] - The top three highest-paid CFOs are Gong Yuda from Guobang Pharmaceutical at 1.93 million yuan, Li Qirong from Zhejiang Pharmaceutical at 1.84 million yuan, and Hou Ning from Xinhua Pharmaceutical at 1.57 million yuan [2] CFO Age Distribution - CFOs aged 40-50 constitute the majority at 36%, while those aged 50-60 account for 33%, and those aged 40 and below make up 26%. Only 5% of CFOs are over 60 years old [1] CFO Educational Background - The educational background of CFOs shows that 2% have a high school diploma, 12% have an associate degree, 65% hold a bachelor's degree, and 21% possess a master's degree. Notably, only one CFO has a high school education [1] Salary Changes - Among CFOs with over two years of tenure, Liu Qingke from Huangshan Capsule experienced the largest salary decrease of 19.04%, while Qian Dan from Nengte Technology saw the highest salary increase of 100.58% [2]